DORADO - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311)

Trial Profile

DORADO - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311)

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Darusentan (Primary)
  • Indications Resistant hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms DORADO
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 16 Jun 2009 Primary endpoint 'Systolic blood pressure' has been met.
    • 16 Jun 2009 Primary endpoint 'Seated blood pressure' has been met.
    • 16 Jun 2009 Primary endpoint 'Diastolic blood pressure' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top